Skip to main content

Upsher-Smith launches generic Onfi

Upsher-Smith Laboratories is launching clobazam tablets 10 and 20 mg, and clobazam oral suspension 2.5 mg/mL.

Upsher-Smith’s clobazam products are the generic version of Lundbeck's Onfi (clobazam) tablets, and Onfi (clobazam) oral suspension.

Clobazam tablets had a market value of approximately $594 million for the 12 months ended August 2018, and the market value of clobazam oral suspension was approximately $255 million for the 12 months ended in August, according to IQVIA data.

“Upsher-Smith’s generic clobazam will provide patients and families with a generic alternative to Onfi,” Upsher-Smith president and CEO Rusty Field said in a statement. “The approval and launch of this product in both tablet and oral suspension forms offer yet another example of our commitment to growing and diversifying our generics portfolio.”
This ad will auto-close in 10 seconds